Abstract
Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Volume: 10 Issue: 2
Author(s): Yaoyu Chen, Cong Peng, Con Sullivan, Dongguang Li and Shaoguang Li
Affiliation:
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Abstract: Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Export Options
About this article
Cite this article as:
Chen Yaoyu, Peng Cong, Sullivan Con, Li Dongguang and Li Shaoguang, Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909326
DOI https://dx.doi.org/10.2174/187152010790909326 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy
Current Drug Targets Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Driving Neural Stem Cells Towards a Desired Phenotype
Current Stem Cell Research & Therapy Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets